Want to see BMRA full AI Analyst Report?
Biomerica (BMRA) Risk Analysis
Risk Overview Q2, 2026
Source: the company's latest filing for the period ended May 31, 2026, filed Aug 31, 2026
Risk Change Over Time
- Share Price & Shareholder Rights - Risk 1Nasdaq's recently adopted minimum Market Value of Listed Securities requirement of $5 million could result in the suspension and delisting of our common stock from Nasdaq.
On July 22, 2026, the SEC approved a new Nasdaq rule (Listing Rules 5450(a)(3) and 5550(a)(6)) requiring companies listed on the Nasdaq Global Market and Nasdaq Capital Market to maintain a minimum Market Value of Listed Securities ("MVLS") of at least $5 million. Under the new rule, if a company's MVLS remains below $5 million for 30 consecutive business days, Nasdaq will issue a Staff Delisting Determination, and trading in the Company's securities will be immediately suspended without any cure or compliance period. This represents a significant departure from Nasdaq's traditional approach to continued listing deficiencies, which typically provides issuers with compliance periods to regain compliance while remaining listed. Although a Nasdaq Hearings Panel may, in its discretion, grant an exception of up to 180 calendar days from the Staff Delisting Determination if a company demonstrates that it can satisfy Nasdaq's initial listing standards, such relief is discretionary, and the suspension from Nasdaq trading is not automatically stayed during any appeal. On July 29, 2026, the new Nasdaq rule was automatically stayed pending further action by the Commission. While the temporary stay delays the rule's effectiveness, it does not alter the SEC's approval of the new continued listing standard. As of the date of this Annual Report, our MVLS may be at or near levels that could implicate this new requirement. Given our current stock price and the number of shares of our common stock outstanding, a sustained decline in our stock price or other adverse market conditions could cause our MVLS to fall below $5 million for 30 consecutive business days, triggering an immediate suspension and delisting from Nasdaq. A delisting under this rule would have the same adverse consequences described above, including reduced liquidity, limited market quotations, diminished analyst coverage, and impaired ability to raise capital. Moreover, the lack of a cure period under this rule means that we would have limited time and recourse to address any such deficiency, and any appeal to a Hearings Panel would require us to demonstrate compliance with Nasdaq's more stringent initial listing standards.
- Accounting & Financial Operations - Risk 2Our revenues have declined, and there is no assurance that we will reverse this trend.
Our net sales decreased from approximately $5,311,000 in fiscal 2025 to approximately $4,453,000 in fiscal 2026, a decline of approximately 16%. This decline was driven in part by distributor ordering patterns and the timing of international shipments. We cannot assure you that our revenues will stabilize or increase in future periods. Continued revenue declines could increase our operating losses, accelerate our use of cash, and increase our dependence on external financing, any of which could materially adversely affect our business, financial condition, and results of operations.
Risk Highlights Q2, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 33
- Share Price & Shareholder Rights - Risk 1AddedNasdaq's recently adopted minimum Market Value of Listed Securities requirement of $5 million could result in the suspension and delisting of our common stock from Nasdaq.
On July 22, 2026, the SEC approved a new Nasdaq rule (Listing Rules 5450(a)(3) and 5550(a)(6)) requiring companies listed on the Nasdaq Global Market and Nasdaq Capital Market to maintain a minimum Market Value of Listed Securities ("MVLS") of at least $5 million. Under the new rule, if a company's MVLS remains below $5 million for 30 consecutive business days, Nasdaq will issue a Staff Delisting Determination, and trading in the Company's securities will be immediately suspended without any cure or compliance period. This represents a significant departure from Nasdaq's traditional approach to continued listing deficiencies, which typically provides issuers with compliance periods to regain compliance while remaining listed. Although a Nasdaq Hearings Panel may, in its discretion, grant an exception of up to 180 calendar days from the Staff Delisting Determination if a company demonstrates that it can satisfy Nasdaq's initial listing standards, such relief is discretionary, and the suspension from Nasdaq trading is not automatically stayed during any appeal. On July 29, 2026, the new Nasdaq rule was automatically stayed pending further action by the Commission. While the temporary stay delays the rule's effectiveness, it does not alter the SEC's approval of the new continued listing standard. As of the date of this Annual Report, our MVLS may be at or near levels that could implicate this new requirement. Given our current stock price and the number of shares of our common stock outstanding, a sustained decline in our stock price or other adverse market conditions could cause our MVLS to fall below $5 million for 30 consecutive business days, triggering an immediate suspension and delisting from Nasdaq. A delisting under this rule would have the same adverse consequences described above, including reduced liquidity, limited market quotations, diminished analyst coverage, and impaired ability to raise capital. Moreover, the lack of a cure period under this rule means that we would have limited time and recourse to address any such deficiency, and any appeal to a Hearings Panel would require us to demonstrate compliance with Nasdaq's more stringent initial listing standards.
- Share Price & Shareholder Rights - Risk 2Sales of our common stock in the public market could lower the market price for our common stock and adversely impact the trading price of our securities.
Future sales by us of a substantial number of shares of our common stock in the public market to raise needed capital, or the perception that such sales may occur, could adversely affect the then prevailing market price of our common stock and could make it more difficult for us to raise funds in the future through a public offering of our securities. On September 28, 2023, we filed a "shelf" registration statement on Form S-3 with the SEC, (the "Shelf Registration Statement"), which was declared effective on September 29, 2023, to replace the expiring "shelf" registration statement on Form S-3 that was filed on July 21, 2020, as amended on September 20, 2020, allowing us to issue up to $20,000,000 in shares of our common stock from time to time. On May 10, 2024, we filed a prospectus supplement to the Shelf Registration Statement with the SEC to facilitate the sale of up to $5,500,000 in common stock through at-the-market ("ATM") offerings, as defined in Rule 415 under the Securities Act (the "2024 ATM Offering"). We have sold shares under the 2024 ATM Offering and may continue to do so the extent the applicable registration statement and prospectus supplement remain effective and available for use. The issuance of additional shares of our common stock, or other securities, could dilute our existing stockholders' ownership interests, potentially depress the market price of our common stock, and impair our ability to raise capital through future equity sales. In June 2026, our certificate of incorporation was amended to increase the number of authorized shares of common stock from 25,000,000 to 300,000,000, significantly increasing the number of shares that may be available for future issuance. The size and impact of future issuances on the market price of our common stock cannot be predicted. Future issuances could result in substantial dilution to existing stockholders. We also have a number of stockholders who own large blocks of our common stock. If one or more of these stockholders were to sell large portions of their holdings in a relatively short time, for liquidity or other reasons, the prevailing market price of shares of our common stock could be negatively affected. In order to obtain additional capital to fund our operations, we may need to issue preferred stock, warrants, convertible debt or other financial instruments that could have liquidation priority, requirements for interest or dividend payments, or other rights and that could be detrimental to existing shareholders' return on their investment in the Company.
- Share Price & Shareholder Rights - Risk 3The price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance.
The stock market can experience significant price and volume fluctuations that are unrelated to the operating performance of individual companies. These broad market fluctuations may cause the market price of our common stock to drop. In particular, our common stock has historically been volatile and may continue to be unpredictable in the future. Factors that could cause fluctuations in our stock price include, but are not limited to: - Announcements by us or our competitors concerning technological innovations or new product introductions. - Regulatory actions or changes, including those by the FDA, SEC, or international regulatory bodies. - Developments or disputes related to patents or intellectual property rights. - Failure to meet current or future regulatory requirements necessary to remain listed on the Nasdaq Capital Market. - Failure to meet the expectations of stock market analysts and investors. - Reporting material weaknesses in our internal controls. - Changes in stock market analyst recommendations or financial estimates regarding our common stock. - Shifts in healthcare policy in the United States or other countries. - Lawsuits or liability claims from shareholders or other parties. - Legal disputes of all kinds or other significant litigation. - Possible recalls of our products or reports of false positive/negative results. - Sales of our common stock or other securities by us or our stockholders. - Changes in trading volume of our common stock. - Variations in quarterly operating results, whether actual or anticipated. - Publication of research reports about us or our industry, or changes in securities analysts' recommendations. - Effects of natural or man-made catastrophic events, including widespread health epidemics. - General stock market conditions and other factors unrelated to our operating performance. - Volatility and disruptions in capital and credit markets due to economic conditions such as rising inflation and interest rates. - Geopolitical events, such as wars, tariffs or political unrest, that impact the markets in which we operate. - Changes in the macroeconomic environment that affect market conditions. Additionally, due to the limited trading volume of our common stock, substantial sales of our stock could adversely impact its market price. While our common stock has been traded on the Nasdaq Capital Market since August 26, 2016, liquidity may be limited, and it could be challenging to liquidate large positions without adversely affecting the stock price.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.
